The opening has been announced of new women’s health products manufacturing plant, which is based in Chile, which is claimed to be the most modern facility of its kind in Latin America.
Family-owned German drugmaker Grünenthal invested $14.5 million to build the 1,150 m2 hormone plant, which is the company’s center of excellence for hormone production in Latin America.
The new facility will initially deliver high quality women’s health products to the Chilean market and – after the pending approval of the relevant regulatory authorities (ANVIMA, ANVISA and COFEPRIS) – it will also provide products for other Latin American markets, including the biggest of the region: Brazil and Mexico. With this investment Grünenthal will improve the access of more than 168 million Latin American women to high quality health products.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze